USANA Health Sciences (USNA) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" USNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in USNA, but not buy additional shares or sell existing shares.
View USNA analyst ratings or view top-rated stocks.

2 brokerages have issued 1-year price targets for USANA Health Sciences' stock. Their USNA share price forecasts range from $53.00 to $56.00. On average, they expect the company's stock price to reach $54.50 in the next twelve months. This suggests that the stock has a possible downside of 13.2%.
View analysts price targets for USNA or view top-rated stocks among Wall Street analysts.

USANA Health Sciences' stock was trading at $53.20 at the beginning of the year. Since then, USNA shares have increased by 18.0% and is now trading at $62.77.
View the best growth stocks for 2023 here.

USANA Health Sciences saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 406,700 shares, an increase of 16.2% from the April 15th total of 350,000 shares. Based on an average daily volume of 78,700 shares, the short-interest ratio is presently 5.2 days. Currently, 3.6% of the company's shares are sold short.
View USANA Health Sciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 25th 2023.
View our USNA earnings forecast.

USANA Health Sciences, Inc. (NYSE:USNA) posted its earnings results on Tuesday, February, 7th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.35 by $0.31. The firm had revenue of $227.96 million for the quarter. USANA Health Sciences had a trailing twelve-month return on equity of 15.31% and a net margin of 6.70%. During the same quarter in the previous year, the company posted $1.03 earnings per share.

ETFs with the largest weight of USANA Health Sciences (NYSE:USNA) stock in their portfolio include Invesco S&P SmallCap Consumer Staples ETF (PSCC), Roundhill Acquirers Deep Value ETF (DEEP), Global X Health & Wellness ETF (BFIT), Pacer US Small Cap Cash Cows 100 ETF (CALF), ETC 6 Meridian Low Beta Equity Strategy ETF (SIXL), RiverFront Dynamic US Flex-Cap ETF (RFFC), First Trust Active Factor Small Cap ETF (AFSM) and First Trust Small Cap Value AlphaDEX Fund (FYT).

USANA Health Sciences updated its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $2.40-$3.30 for the period, compared to the consensus estimate of $2.85. The company issued revenue guidance of $875.00 million-$950.00 million, compared to the consensus revenue estimate of $935.33 million.

68 employees have rated USANA Health Sciences Chief Executive Officer Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among the company's employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

USANA Health Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.04%), Renaissance Technologies LLC (6.28%), Pzena Investment Management LLC (4.24%), Dimensional Fund Advisors LP (3.11%), State Street Corp (2.22%) and Acadian Asset Management LLC (1.38%). Insiders that own company stock include Brent Neidig, Daniel A Macuga, Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Gilbert A Fuller, Jim Brown, John Turman Fleming, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Robert Auciaux, Timothy E Wood and Walter Noot.
View institutional ownership trends.

Shares of USNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of USNA stock can currently be purchased for approximately $62.77.

USANA Health Sciences (NYSE:USNA) has a market capitalization of $1.21 billion and generates $998.60 million in revenue each year. The company earns $69.35 million in net income (profit) each year or $3.39 on an earnings per share basis.

The company employs 1,900 workers across the globe.

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The official website for the company is www.usana.com. The company can be reached via phone at (801) 954-7100, via email at investor.relations@usanainc.com, or via fax at 801-954-7300.